Meeting its primary endpoint in a Phase III trial, Ceplene proved itself not only as a potential lifesaver for acute myeloid leukemia patients, but also as an immune modulator that can show benefit in different classes of cancer. (BioWorld Today)

Enabling IntraBiotics Pharmaceuticals Inc. to ramp up its clinical programs for iseganan, the company raised $39 million gross in a public stock offering Wednesday. (BioWorld Today)